Results 31 to 40 of about 7,267,063 (234)
A pipeline analysis of advanced therapy medicinal products
Drug Discovery Today, 2023 Advanced therapy medicinal products (ATMPs) are innovative biological products categorised as either gene, somatic cell, tissue-engineered or combined therapies. As of March 2022, 12 ATMPs are marketed in the EU and UK. We identified 482 unique ATMPs within 616 technology records from the National Institute for Health and Care Research Innovation ...
Georgina C. Wilkins +5 more
openaire +3 more sources
Surgery Versus ATMPs: An Example From Ophthalmology
Frontiers in Bioengineering and Biotechnology, 2020 Advanced therapy medicinal products (ATMPs) are the new frontier of medicine. Advanced therapy medicinal products are set out to satisfy unmet medical needs and provide new innovative, cutting-edge therapies for serious or life-threatening diseases, thus
Federica M. Magrelli +3 more
doaj +1 more source
Molecules, 2021 Cartilage has a limited inherent healing capacity after injury, due to a lack of direct blood supply and low cell density. Tissue engineering in conjunction with biomaterials holds promise for generating cartilage substitutes that withstand stress in ...
Jirapat Namkaew +5 more
doaj +1 more source
Advanced Therapy Medicinal Products - a Multiple Challenge [PDF]
Transfusion Medicine and Hemotherapy, 2013 The passage of European Union Regulation 1394/2007/EC [1] on Advanced Therapy Medicinal Products (ATMPs) complements the European Community code relating to medicinal products for human use [2, 3]. This regulation is thus immediately valid in all member states of the European Union for gene therapeutics, somatic cellular therapeutics, and tissue ...
Axel, Pruss, Henk, Garritsen
openaire +2 more sources
Methodological Approaches to Risk Management of Advanced Therapy Medicinal Products
Разработка и регистрация лекарственных средств, 2023 Introduction. Advanced therapy medicinal products (ATMPs) rely on recent advances in medical science, but alongside with potential benefits they may also bring safety concerns for patients. The inherent complexity of the ATMP production and use calls for
A. A. Taube, N. Yu. Velts
doaj +1 more source
Frontiers in Medicine, 2022 Many RNA-based drugs, both vaccines and non-vaccines, are under development or even approved. They include coding mRNAs and non-coding (nc) RNAs among them antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), micro-RNAs (miRNAs), small ...
Mathieu Guerriaud, Evelyne Kohli
doaj +1 more source
Advanced therapy medicinal products: current and future perspectives [PDF]
Journal of Market Access & Health Policy, 2016 Advanced therapy medicinal products (ATMPs) are innovative therapies that encompass gene therapy, somatic cell therapy, and tissue-engineered products. These therapies are expected to bring important health benefits, but also to substantially impact the pharmaceuticals budget.The aim of this study was to characterise the ATMPs in development and ...
Hanna, Eve +3 more
openaire +2 more sources
Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
Neurologijos seminarai, 2023 Multiple sclerosis is a chronic autoimmune disease of the central nervous system. Multiple sclerosis causes demyelination, impaired nervous system function, and eventually neurodegeneration. Microglia are cells of the central nervous system that develop
P. Valiukevičius +2 more
doaj +3 more sources
, 2023 International audienceAdvanced Therapy Medicinal Products (ATMPs) is a European classification of medicinal products based on genes, cells and tissues specifically regulated in the European Union (EU) from the entry into force of Regulation (EC) No 1394 ...
Delage, Auxane +3 more
core +3 more sources
‘Relais actors’ and co-decision first reading agreements in the European Parliament : the case of the advanced therapies regulation [PDF]
, 2011 The processing of the advanced therapies regulation is of particular interest to scholars of the European Union's (EU) legislative process and students of the European Parliament (EP) because it provides a case study which throws light upon assumptions ...
Judge, D., Earnshaw, D.
core +4 more sources